The role of AIM2 may be controversial in different cancer types; in our study, upregulation of AIM2 was associated with shorter OS time in PDAC, consistently with that in nasopharyngeal carcinoma and non-small cell lung cancer [28]. This evidence concerns the gene AIM2 and non-small cell lung carcinoma.